Analysts’ Viewpoint
Asthma is a chronic lung disease that affects people of all ages, worldwide, which places a heavy cost on both individuals and healthcare systems. The consequences include a significant decline in one's quality of life and even early death. Children, adolescents, and adults all display similar symptoms of asthma; however, adolescents suffer the greatest burden in terms of the prevalence and severity of the disease. Furthermore, regulatory bodies are hastening the approval of biologics, and healthcare professionals are presently more likely to include biologics in their asthma treatment plans.
In summary, increased awareness about asthma therapy has ushered in a new age for asthma biologics, characterized by increased demand, creative solutions, and more access to these game-changing medications. However, a number of the side-effects associated with asthma drugs, including dry mouth, elevated heart rate, nausea, headaches, and tremors, are expected to somewhat restrain the asthma biologics market growth in the near future.
Biologics are used to treat severe cases of asthma that are difficult to control with conventional inhaled medicines. Biologics can assist to enhance lung function, lessen the requirement for oral corticosteroids, and lessen the severity of asthma symptoms.
Numerous biologics have been licensed for the treatment of asthma. These biologics focus on several disease-related processes, including inflammation, allergic reaction, and airway remodeling. Asthma biologics minimize asthma attacks, alleviate symptoms, and reduce dependency on oral steroids by targeting pathways that cause lung inflammation. They are routinely administered as an injection or infusion in hospitals, or patients can self-inject at home, depending on the biologic being taken.
Asthma treatment primarily comprises FDA-approved asthma biologics, which include Omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor), dupilumab (anti-IL-4/IL-13 receptor), and tezepelumab.
Increase in awareness among patients, healthcare providers, and communities regarding asthma management and the array of treatment choices available are boosting the acknowledgment of the paramount importance of achieving improved control over asthma, especially in cases that are severe and unmanageable.
This heightened awareness is prompting individuals to actively seek more effective solutions that extend beyond the traditional use of inhalers and oral medications. One of the key asthma biologics market trends witnessed across the globe is the growing popularity of asthma biologics as an alternative treatment for asthma. This is because asthma biologics are characterized by their precision in addressing the root causes of inflammation and specific molecular pathways implicated in asthma.
Furthermore, individuals are becoming increasingly health-conscious, engaging in practices such as breathing exercises and yoga, and promptly consulting healthcare professionals. This heightened awareness and proactive approach to asthma management are contributing significantly to controlling asthma and, consequently, fueling the asthma treatment and biologics market.
Moreover, healthcare providers are currently more inclined to incorporate biologics into their asthma treatment regimens, and regulatory agencies are expediting approvals for these therapies. People with asthma and organizations dedicated to asthma control and education work together on World Asthma Day (May 3, 2022) and throughout May to spread awareness about asthma, raise awareness about asthma, and enhance the lives of all people with asthma.
Obtaining a worldwide outlook on asthma management is crucial, as it allows us to pinpoint existing deficiencies and formulate strategies for implementing interventions that can bolster asthma control across diverse healthcare environments.
In terms of drug class, the interleukin inhibitors segment held significant asthma biologics market share in 2022. The interleukin inhibitors segment is predicted to expand during the forecast period due to Dupixent. Dupixent is a human monoclonal antibody that blocks the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways.
Several nations across the world have approved Dupixent for the treatment of specific patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), or eosinophilic esophagitis in distinct age demographics. Dupixent is currently licensed for all of these indications in the U.S., while in the European Union, Japan, and more than 60 other countries, it has received approval for one or more of these indications. Globally, more than 400,000 people have received treatment.
Based on distribution channel, the retail pharmacies of asthma biologics market segmentation accounted for the largest share of the global asthma biologics market value in 2022. Retail pharmacies often have pharmacists who can educate patients, thus ensuring that individuals understand how to use biologics effectively and safely.
Retail pharmacies also offer convenience and accessibility to patients with asthma. These pharmacies are commonly located in residential areas. Increase in number of retail pharmacies worldwide, availability of asthma biologics in these settings, and growth in preference among patients for easy access to medication and advice from trained pharmacists are likely to boost segment growth during the forecast period
According to the latest regional asthma biologics market analysis, North America dominated the global market due to the high prevalence of respiratory disorders, well-established healthcare infrastructure, and high healthcare spending. The region is home to several leading pharmaceutical companies that have a strong presence in the global asthma biologics industry and continue to develop innovative therapies.
On the other hand, the asthma biologics market size in Asia Pacific is expected to expand at a rapid pace due to the growing geriatric population, rapidly expansion of healthcare infrastructure, and increase in government initiatives to improve access to healthcare services across the region.
The global asthma biologics business is highly consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies implemented by leading players in the global market. Amgen, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and other prominent players operate in the global asthma biologics market.
Key players in the asthma biologics market have been profiled based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size Value in 2022 | US$ 6.5 Bn |
| Market Forecast Value in 2031 | More than US$ 19.2 Bn |
| Growth Rate (CAGR) | 12.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2020 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Disease Prevalence Rate with Key Countries, T2 Inflammation Disease State Overview, Pipeline Analysis, Major Biologics Brand Value Forecast. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global market was valued at US$ 6.5 Bn in 2022
It is projected to reach a value of more than US$ 19.2 Bn by 2031
The global business is anticipated to grow at a CAGR of 12.5% from 2023 to 2031
Rise in awareness about asthma treatment and control of asthma
North America is expected to account for major share of the global market during the forecast period
Amgen, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Asthma Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Asthma Biologics Market Analysis and Forecast, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. T2 Inflammation Disease State Overview
5.3. Disease Prevalence Rate with Key Countries
5.4. COVID-19 Pandemics Impact on Industry
6. Global Asthma Biologics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017 - 2031
6.3.1. Selective Immunosuppressants
6.3.2. Interleukin Inhibitors
6.3.3. Others
6.4. Market Attractiveness, by Drug Class
7. Global Asthma Biologics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
7.3.1. Retail Pharmacies
7.3.1.1. E-commerce
7.3.1.2. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Asthma Biologics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Asthma Biologics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017 - 2031
9.2.1. Selective Immunosuppressants
9.2.2. Interleukin Inhibitors
9.2.3. Others
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
9.3.1. Retail Pharmacies
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017 - 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Asthma Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017 - 2031
10.2.1. Selective Immunosuppressants
10.2.2. Interleukin Inhibitors
10.2.3. Others
10.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
10.3.1. Retail Pharmacies
10.3.1.1. E-commerce
10.3.1.2. Others
10.4. Market Value Forecast, by Country, 2017 - 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Asthma Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017 - 2031
11.2.1. Selective Immunosuppressants
11.2.2. Interleukin Inhibitors
11.2.3. Others
11.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.3.1. Retail Pharmacies
11.3.1.1. E-commerce
11.3.1.2. Others
11.4. Market Value Forecast, by Country, 2017 - 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country
12. Latin America Asthma Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017 - 2031
12.2.1. Selective Immunosuppressants
12.2.2. Interleukin Inhibitors
12.2.3. Others
12.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.3.1. Retail Pharmacies
12.3.1.1. E-commerce
12.3.1.2. Others
12.4. Market Value Forecast, by Country, 2017 - 2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country
13. Middle East & Africa Asthma Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017 - 2031
13.2.1. Selective Immunosuppressants
13.2.2. Interleukin Inhibitors
13.2.3. Others
13.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.3.1. Retail Pharmacies
13.3.1.1. E-commerce
13.3.1.2. Others
13.4. Market Value Forecast, by Country, 2017 - 2031
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. Amgen, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. AstraZeneca
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. GSK plc
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. Strategic Overview
14.3.5.5. SWOT Analysis
14.3.6. Regeneron Pharmaceuticals, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Sanofi
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Teva Pharmaceutical Industries Ltd.
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
List of Tables
Table 01: Global Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: North America Asthma Biologics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 06: North America Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Asthma Biologics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: Europe Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 09: Europe Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Asthma Biologics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 11: Asia Pacific Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Asia Pacific Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Asthma Biologics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 14: Latin America Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Latin America Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East & Africa Asthma Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Asthma Biologics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 18: Middle East & Africa Asthma Biologics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Asthma Biologics Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 03: Global Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 04: Global Asthma Biologics Market Revenue (US$ Mn), by Selective Immuno-suppressants, 2017–2031
Figure 05: Global Asthma Biologics Market Revenue (US$ Mn), by Interleukin Inhibitors, 2017–2031
Figure 06: Global Asthma Biologics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 07: Global Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 08: Global Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Figure 09: Global Asthma Biologics Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 10: Global Asthma Biologics Market Revenue (US$ Mn), by E-commerce, 2017–2031
Figure 11: Global Asthma Biologics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 12: Global Asthma Biologics Market Value Share Analysis, by Region, 2022 and 2031
Figure 13: Global Asthma Biologics Market Attractiveness, by Region, 2023-2031
Figure 14: North America Asthma Biologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 15: North America Asthma Biologics Market Value Share (%), by Country, 2022 and 2031
Figure 16: North America Asthma Biologics Market Attractiveness Analysis, by Country, 2023–2031
Figure 17: North America Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 18: North America Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 19: North America Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 20: North America Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Figure 21: Europe Asthma Biologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 22: Europe Asthma Biologics Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 23: Europe Asthma Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 24: Europe Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 25: Europe Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 26: Europe Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 27: Europe Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Figure 28: Asia Pacific Asthma Biologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: Asia Pacific Asthma Biologics Market Value Share (%), by Country, 2022 and 2031
Figure 30: Asia Pacific Asthma Biologics Market Attractiveness Analysis, by Country, 2023–2031
Figure 31: Asia Pacific Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 32: Asia Pacific Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 33: Asia Pacific Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 34: Asia Pacific Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Figure 35: Latin America Asthma Biologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Latin America Asthma Biologics Market Value Share (%), by Country, 2022 and 2031
Figure 37: Latin America Asthma Biologics Market Attractiveness Analysis, by Country, 2023–2031
Figure 38: Latin America Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 39: Latin America Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 40: Latin America Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 41: Latin America Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Figure 42: Middle East & Africa Asthma Biologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 43: Middle East & Africa Asthma Biologics Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 44: Middle East & Africa Asthma Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 45: Middle East & Africa Asthma Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 46: Middle East & Africa Asthma Biologics Market Attractiveness, by Drug Class, 2023-2031
Figure 47: Middle East & Africa Asthma Biologics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Middle East & Africa Asthma Biologics Market Attractiveness, by Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Asthma Biologics Market
